Ceribell Reports First Quarter 2025 Financial Results

About this update from Ceribell, Inc.

[{"type":"image","alt":"Ceribell","displaySize":"","headline":null,"caption":"Ceribell","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":300,"url":"https://media.zenfs.com/en/globenewswire.com/3cc07cfbaa616f81a3c97d674cb67ebe"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/9_NKyLayYss_HJf8vUA9xQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTQyMDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/3cc07cfbaa616f81a3c97d674cb67ebe","width":300,"height":300}},"lazy":false},{"type":"text","content":"SUNNYVALE, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today reported financial results for the quarter ended March 31, 2025.","length":298,"tagName":"p"},{"type":"text","content":"First Quarter 2025 & Recent Highlights ","length":42,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Reported total revenue of $20.5 million in the first quarter of 2025, a 42% increase compared to the same period in 2024","length":120,"tagName":"p"}]},{"val":[{"type":"text","content":"Ended the quarter with 558 total active accounts","length":48,"tagName":"p"}]},{"val":[{"type":"text","content":"Achieved gross margin of 88% in the first quarter of 2025","length":57,"tagName":"p"}]},{"val":[{"type":"text","content":"Received U.S. Food and Drug Administration 510(k) clearance for expansion of Clarity™ algorithm indication, becoming the first seizure detection algorithm indicated for patients ages 1 and older ","length":195,"tagName":"p"}]},{"val":[{"type":"text","content":"Became the first medical device company to receive FedRAMP High authorization from the U.S. federal government","length":110,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":530,"olType":false},{"type":"text","content":"“We are pleased with our strong start to the year as we further expanded our account base while benefiting from accelerated adoption of the Ceribell system,” said co-founder and CEO Jane Chao, Ph.D. “Looking ahead, we see 2025 as another momentous year of growth for Ceribell as we execute our proven playbook to drive adoption through physician education and continued investment in our commercial organization. We also look forward to offering our pediatric Cla...

More updates from Ceribell, Inc.